Abstract
A small proportion of lung adenocarcinomas harbour ROS1 gene arrangements and are sensitive to ROS1 tyrosine kinase inhibitors. In Australia, ROS1 immunohistochemistry (IHC) is used to screen for ROS1 rearrangements in lung adenocarcinomas followed by confirmatory molecular testing such as fluorescence in situ hybridisation (FISH), if other genetic driver alterations are negative. The optimal threshold for determining ROS1 IHC positivity is not well defined, and this study aims to determine the best threshold for ROS1 IHC screening to identify all ROS1 rearranged lung adenocarcinomas.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
